Insiders Trades
Simulations Plus, Inc. Stock: price and insider trades · United States
Simulations Plus, Inc.: what insiders have been doing
Simulations Plus, Inc., classified in the Healthcare & Pharma sector, is a listed company based in Lancaster, United States, founded in 1996. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Simulations Plus, Inc. logged 38 filings by 11 insiders.
Only sales appear on the open market, 9 sales in all totalling €345k, filed by 4 insiders. The totals exclude 1 filing filed without an amount. Woltosz Walter S filed the largest sale, €194k, on 5 May 2026, which represents 0.068% of the company's market value.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 38 filings here. Since 2016, the database holds no purchases and 70 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 August 2025 lists revenue at 79.2 m USD and net income at -64.7 m USD.
Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
202
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€24M
70 ops. · all time
Who traded when
BuySaleWalter S. Woltosz10 sales
John Anthony DiBella II5 sales
LaVange Lisa3 sales
Daniel L. Weiner1 sale
Jill Fiedler-Kelly1 sale
Analyst consensus: bullish or bearish?
Analysts rate Simulations Plus, Inc. Hold (neutral), based on 1 analysts. Average price target: US$18.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,632 of 24,148 companies
42.2
score / 100
Value29
Quality55
FCF yld3.8%
Earn yld-17%
EV/EBITDA25.5x
ROE6.2%
Gross mgn58%
Net mgn-82%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended August 2025 · cache
US$18.50
Analyst consensus
1 analystsHold
US$18.50Target US$18.50(0%)US$18.50
Income statement
RevenueUS$79.2M
Gross profitUS$46.2M58% margin
EBITDAUS$14.7M19% margin
Net income-US$64.7M9.9% margin
Valuation
PER (trailing)46.3x
PER (forward)20.9x
P/Book2.7x
Beta1.32
Balance sheet & cash
Market capUS$374.2M
Total debtUS$616k
Free Cash FlowUS$14.4M
Debt / Equity0%
Profitability & ownership
ROE6.2%
ROA5.5%
% insiders16.9%
% institutions79.2%
Last declaration on 6 October 2026
Declarations202 total
85,140 shares@ US$18.500.42% mcap63.9% of flowCommon StockSEC:0001023459-26-000091:0
17,173 shares@ US$18.500.085% mcap100.0% of flowCommon StockSEC:0001023459-26-000089:0
77,817 shares@ US$18.500.39% mcap92.5% of flowCommon StockSEC:0001023459-26-000087:0
14,589 shares@ US$18.500.072% mcap62.5% of flowCommon StockSEC:0001023459-26-000083:0
16,547 shares@ US$18.500.082% mcap57.3% of flowCommon StockSEC:0001023459-26-000081:0
3,202,131 shares@ US$18.5015.85% mcap69.6% of flowCommon StockSEC:0001023459-26-000079:0
2,100 shares@ US$18.500.010% mcap31.7% of flowCommon StockSEC:0001023459-26-000085:0
1,000 shares@ US$18.280.0048% mcap2.0% of flowCommon StockSEC:0001544167-26-000013:0
3,000 shares@ US$18.230.014% mcap100.0% of flowCommonSEC144:0001950047-26-007560
1,000 shares@ US$18.360.0049% mcap2.0% of flowCommon StockSEC:0001544167-26-000011:0
4,177 shares@ US$18.440.021% mcap0.3% of flowCommon StockSEC:0001222526-26-000012:0
4,177 shares@ US$18.310.021% mcap100.0% of flowCommonSEC144:0001950047-26-006699
5,250 shares@ US$16.370.023% mcap62.5% of flowCommonSEC144:0001950047-26-006210
1,050 sharesCommon StockSEC:0001899390-26-000006:0
1,050 sharesCommon StockSEC:0001899390-26-000006:1
3,150 shares@ US$16.320.014% mcap37.5% of flowCommonSEC144:0001950047-26-006114
1,000 shares@ US$16.500.0039% mcap1.8% of flowCommon StockSEC:0001544167-26-000008:0
1,000 shares@ US$10.050.0030% mcap8.2% of flowCommon StockSEC:0001899390-26-000004:0
1,000 shares@ US$14.980.0045% mcap1.6% of flowCommon StockSEC:0001544167-26-000006:0
15,000 shares@ US$15.130.068% mcap0.8% of flowCommon StockSEC:0001222526-26-000007:0
2,117 shares0Common StockSEC:0001134615-26-000004:0
2,117 shares0Common StockSEC:0001899498-26-000004:0
2,117 shares0Common StockSEC:0001627832-26-000007:0
2,117 shares0Common StockSEC:0001222526-26-000005:0
1,000 shares@ US$13.370.0040% mcap1.4% of flowCommon StockSEC:0001544167-26-000004:0
25 of 202 declarations
About Simulations Plus, Inc.
Simulations Plus, Inc. (NASDAQ: SLP) is a U.S.-based specialist in modeling and simulation software and scientific consulting for the pharmaceutical and biotechnology industries. Listed on the U.S. NASDAQ market, the company is headquartered in Lancaster, California, United States. It was founded in 1996 and has evolved into a recognized provider of decision-support tools used in drug discovery, development, and optimization. ([fintel.io](https://fintel.io/doc/sec-simulations-plus-inc-1023459-10k-2024-october-30-20026-896?utm_source=openai))
The business model is built on two main pillars: software and consulting services. On the software side, Simulations Plus markets best-known products such as GastroPlus, a widely used platform for simulating absorption, pharmacokinetics, and pharmacodynamics, along with additional tools for simulation and molecular-property prediction. The company also emphasizes capabilities in cheminformatics, biosimulation, simulation-enabled intelligence, clinical operations technology, and medical communications. ([stockanalysis.com](https://stockanalysis.com/stocks/slp/company/?utm_source=openai))
Read moreShow less
Its competitive position comes from a fairly uncommon combination: an established scientific software base, regulatory and domain expertise, and consulting services that support pharmaceutical clients across the development lifecycle. In a market where faster development, lower R&D costs, and better trial efficiency are increasingly important, this offering addresses a structural need. The company serves an international customer base, and its annual reporting has referenced independent distributors in Japan, China, India, South Korea, and Brazil, underscoring a commercial footprint beyond North America. ([fintel.io](https://fintel.io/doc/sec-simulations-plus-inc-1023459-10k-2024-october-30-20026-896?utm_source=openai))
Recent milestones highlight the company’s continued relevance for investors following specialized healthcare software names. In 2025, Simulations Plus released quarterly earnings updates and guidance revisions, keeping the stock on the radar of investors looking at niche healthcare technology and small-cap software companies. Management also described the company as a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications, while providing fiscal 2026 outlook commentary. In addition, Simulations Plus announced an investment in Nurocor, a clinical development technology company, suggesting a strategy to broaden its solution ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1023459/000102345925000051/pressrelease10222025.htm?utm_source=openai))
For French-speaking investors, Simulations Plus is best viewed as a specialized science-and-software name with exposure to global pharma innovation, a clear U.S. NASDAQ listing, and a differentiated niche positioning supported by recurring client relationships and mission-critical tools.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
